E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Recurrent Glioblastoma Multiforme |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10018337 |
E.1.2 | Term | Glioblastoma multiforme |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the safety and tolerability (defined as the Maximum Tolerated Dose (MTD)) of Delta-24-RGD Adenovirus administered by Convection Enhanced Delivery (CED) to the tumor and the surrounding infiltrated brain in patients with recurrent Glioblastoma Multiforme. |
|
E.2.2 | Secondary objectives of the trial |
To determine the Progression Free Survival (PFS), Overall Survival (OS), and tumor response rate in patients with recurring tumors amenable for surgical resection and treated at the MTD. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients with histologically proven primary Glioblastoma Multiforme (GBM) will be eligible for this protocol. 2. Patients must show unequivocal evidence for tumor recurrence or progression by MRI scan within 3 weeks prior to registration after failing prior resection (surgical or biopsy) and radiation- and or chemotherapy. 3. Recurring tumors must either be accessible for surgery, or, when not accessible for surgery meet the following criteria: - unifocal - midline shift ≤ 0.5 cm - no radiological signs of uncal herniation 4. All recurring tumors must be restricted to one hemisphere, without signs of subependymal spreading. 5. Before start of virus treatment histological analysis of the resected, or biopsied tumor recurrence must confirm the diagnosis of GBM (based on frozen section). 6. Patients may or may not have had prior chemotherapy. 7. Patients must be able to read and understand the informed consent document and must sign and date the informed consent. Procedures to obtain such informed consent should be according to ICH-GCP, the local regulatory requirement and the rules followed at the institute. 8. Patients must be > 16 and < 75 years old. 9. Patients must have a Karnofsky performance status rating > 70 % (Appendix 2 of the protocol). 10. Patients must have recovered from the toxic effects of prior therapy. For example, they must be at least two weeks after vincristine, 6 weeks after nitrosoureas, 3 weeks after procarbazine or temozolamide administration, and 6 weeks after radiation therapy. 11. If sexually active, patients must be willing to use barrier contraception for the duration of the study. 12. Patients must have adequate hepatic, renal and bone marrow function, defined as • absolute neutrophil count (ANC) > 1,5* 109/L • platelet count of > 100* 109/L • ALT (SGPT), AST (SGOT) and Alkaline Phosphatase ≤ 2 times ULN • total bilirubin <1.5 mg/dl • creatinine <1.5 times ULN • urea (BUN) <1.5 times ULN
|
|
E.4 | Principal exclusion criteria |
1. Patients with active uncontrolled infection, signs of active viral infection, upper pulmonary infection and flu-like signs. Patients with presence of adenovirus in pre-treatment throat-swab sample or serum as detected by PCR assay. All patients must be afebrile (<38.0°C) at the start of therapy. 2. Evidence of bleeding diathesis or use of anticoagulant medication. 3. Patients with systemic diseases or other unstable conditions which may be associated with unacceptable anesthetic/ operative risk and/or which would not allow safe completion of this study protocol, e.g. uncontrolled seizures, steroid dependence. 4. Because of the potential risk of a recombinant virus containing a gene involved in cellular growth regulation and differentiation which could potentially affect a developing fetus or growing infant, females who are pregnant, at risk of pregnancy, or breast feeding a baby during the study period are excluded. 5. Because of the potential risk of serious infection in immune-compromised individuals, patients with HIV infection are excluded. 6. Patients with a known germline deficit in the retinoblastoma gene or its related pathways. 7. Patients with other primary malignancy than GBM. However, patients with curatively treated carcinoma-in situ or basal cell carcinoma or patients who have been disease-free for at least 2 years and not using any anti-cancer therapy, are eligible.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoints of this study are: - To determine the Maximum Tolerated Dose - To evaluate the safety of the study treatment |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |